About Event

Welcome to the Cytokine-Based Cancer Immunotherapies Summit

The renewed interest in the anti-tumour properties of cytokines has led to an increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs.

Soluble factors within the tumor microenvironment (TME) orchestrating a variety of wide-ranging biologic effects and interventions in this field can help stimulate immunotherapeutic responsiveness. The virtual Cytokine-Based Cancer Immunotherapies Summit has been set up to give drug developers insight into the latest clinical results and stimulate discussions around how to take immuno-oncology combinations forward.

This is your opportunity to join your peers from industry and academia to discuss key topics including:

imageedit_4_4883615109

Determining the underlying mechanisms of T-cell exclusion from the tumor in order to turn cold tumors ‘hot’ with Roche, Novartis and Werewolf Therapeutics

imageedit_4_4883615109

Optimize cytokine engineering to ensure stability and improve the favorable risk benefit profile with Synthekine, Alkermes and John Hopkinsh 

imageedit_4_4883615109

Overcome toxicity challenges by ensuring tumor targeting is selective and therefore enhances the anti-tumor response with SQZ Biotechnologies, IGM Biosciences, CytomX and Philogen

imageedit_4_4883615109

Take a deep dive into preclinical cancer models covering both in-vitro and in-vivo studies and how these are unveiling the most favoured pharmaceuticals properties of therapeutic cytokines with John Hopkins and University of Western Australia

imageedit_4_4883615109

Uncover the latest data coming out of the clinic of cytokines in combination with checkpoint inhibitors and monoclonal anitbodies with National Cancer Institute 

Companies Set to Attend:

Cytokine-Based Cancer Immunotherapies Summit - Companies attending Banner